This summer we went across Canada and met with all the large private payers, large insurance companies. One of the interesting things right now is that all the payers, whether public or private, are very anxious to see biosimilars in the marketplace. They're looking for them. They want to generate the competition, etc. But one of the things we found is a great deal of resistance right now from patient groups, prescriber groups. I think some of it, frankly, is fomented by some of the originator companies that have been selling these products for more than 20 years. They have created some concern about the biosimilars, but these are products approved by Health Canada as being similar and having no significant therapeutic differences between them and the originator products.
I think in terms of sales, biologics are now closing in on $6 billion a year spent in Canada. Biosimilars now have about $7 million, a tiny fraction. We're just at the beginning of the wave of biosimilar products coming into Canada.